뒤로
Gossamer Bio Inc(GOSS) 가격
GOSS 주가 차트
GOSS 주가 예측
Gossamer Bio Inc
$2.52
2.85%
$0.06
종가: Jan 16, 16:00:00 GMT-5
$2.59
3.16%
$0.07
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$2.45
시가
$2.47
일일 범위
$2.45 - $2.64
52주 범위
$0.76 - $3.87
거래량
3.8M
평균 거래량
3.8M
EPS(TTM)
-0.69
배당수익률
--
시가총액
$601.7M
GOSS란 무엇인가요?
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 144 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.